FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127467> ?p ?o ?g. }

• W4310127467 endingPage "9827" @default.
• W4310127467 startingPage "9824" @default.
• W4310127467 abstract "Background: Activating mutations in KIT are infrequently observed in myeloid neoplasms, but are a pathognomonic finding in systemic mastocytosis (SM) where the hotspot D816V variant is documented in 90-95% of patients. In SM, KIT variants may occur at a low variant allele frequency (VAF) below the limits of detection of most commercial next generation sequencing (NGS) assays necessitating digital droplet PCR (ddPCR) for accurate detection. Aggressive SM often presents concurrently with an associated hematologic neoplasm (SM-AHN). Chronic myelomonocytic leukemia (CMML) is the most frequently co-occurring hematologic malignancy, but KIT mutations are infrequently detected by conventional NGS. The limitations in detecting KIT variants by NGS and increased frequency of CMML in SM-AHN suggest that subclonal KIT mutations may be underrecognized in CMML. Further, identification may have prognostic and therapeutic implications given the emergence of KIT-targeted therapies in SM. Methods: A multicenter, retrospective study was performed to assess the prevalence of subclonal KIT D816V mutations in CMML patients and examine clinical implications. Eligible patients had pathologically confirmed CMML by WHO 2017 criteria, with available bone marrow (n=59) or peripheral blood (n=14) sample obtained prior to therapy. Samples underwent DNA sequencing using a 285-gene NGS panel (QIAseq), with a VAF threshold of 5% utilized for variant calling. KIT D816V mutations were assessed by ddPCR, with limit of detection of 0.03%. Clinical data was collected from baseline and follow up for phenotypic and prognostic comparisons. Fishers exact and Chi-square tests were used to compare categorical variables and the Mann-Whitney test for continuous variables. The Kaplan-Meier method was used to estimate overall survival (OS), with the log rank test used to compare survival between groups. The study was approved by institutional review boards at each institution. Results: A total of 73 patients were included with a median age of 71, and 66% were male. By WHO criteria, 50% were classified as CMML-0, 28% CMML-1, and 22% CMML-2; 59% of patients had proliferative CMML by FAB criteria. KIT D816V mutations were detected in 15 patients (21%) by ddPCR, compared to two (3%) by NGS. The median VAF of mutations detected by ddPCR was 0.06%, whereas the two variants detected by NGS had VAFs of 44.1% and 47.0%. Baseline characteristics of KIT wild-type (WT) and mutated (MUT) patients are detailed in Table 1. KIT MUT patients had lower white blood cell (p=0.007) and absolute monocyte counts (p=0.04), less frequent splenomegaly (p=0.05), more frequent karyotype abnormalities (p=0.14), and lower frequency of proliferative disease by FAB criteria (p=0.01). There was a median of 4 variants (range 0-7) detected per patient by NGS, and the most frequently mutated genes were TET2 (59%), SRSF2 (44%), ASXL1 (33%),RUNX1 (25%), and NRAS (25%). KIT MUT patients had a median of 3 total variants (range 0-6) detected by NGS compared to 4 (range 0-7) in KIT WT (p=0.63). There was a trend toward higher frequency of SF3B1 (23% vs. 5%, p=0.07) mutations in KIT MUT patients. Conversely, no mutations were observed in KRAS or CBL in KIT MUT patients, compared to 14% and 16% in KIT WT, respectively (p=0.34, p=0.20). When evaluating mutations in signaling pathways, there was a trend toward lower frequency in KIT MUT patients compared to WT (31% vs. 59%, p=0.12). With a median follow up of 48 months, median OS of the cohort was 30 months. KIT MUT patients demonstrated an OS of 27.5 months compared to 30 months in WT patients (HR 1.06, p=0.87). Transformation to AML was observed in 42% of KIT MUT patients compared to 29% of WT patients (p=0.49). A similar proportion of patients were treated with hypomethylating agents (HMAs), with a response rate of 14% in KIT MUT patients compared to 32% in WT (p=0.63), and complete remission rates of 0% vs. 27%, respectively. Conclusions: This study is the first to document the prevalence of subclonal KIT D816V mutations by ddPCR in CMML, revealing a high prevalence in comparison to detection by standard NGS assays. While sample size limited statistical comparisons, KIT mutations were associated with distinct phenotypic features, including less proliferative disease and poor response to HMAs. Given the efficacy of KIT inhibitors in SM-CMML, these findings could represent an avenue for targeted therapy in CMML. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127467 created "2022-11-30" @default.
• W4310127467 creator A5006107530 @default.
• W4310127467 creator A5010075752 @default.
• W4310127467 creator A5012925920 @default.
• W4310127467 creator A5015788207 @default.
• W4310127467 creator A5020631581 @default.
• W4310127467 creator A5022353898 @default.
• W4310127467 creator A5023810956 @default.
• W4310127467 creator A5029369362 @default.
• W4310127467 creator A5041754278 @default.
• W4310127467 creator A5047764826 @default.
• W4310127467 creator A5053254720 @default.
• W4310127467 creator A5056921013 @default.
• W4310127467 creator A5058195823 @default.
• W4310127467 creator A5060452476 @default.
• W4310127467 creator A5062180760 @default.
• W4310127467 creator A5067600974 @default.
• W4310127467 creator A5077151480 @default.
• W4310127467 creator A5087964828 @default.
• W4310127467 creator A5089354375 @default.
• W4310127467 creator A5091318797 @default.
• W4310127467 date "2022-11-15" @default.
• W4310127467 modified "2023-10-14" @default.
• W4310127467 title "Subclonal <i>KIT</i> D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features" @default.
• W4310127467 doi "https://doi.org/10.1182/blood-2022-164816" @default.
• W4310127467 hasPublicationYear "2022" @default.
• W4310127467 type Work @default.
• W4310127467 citedByCount "0" @default.
• W4310127467 crossrefType "journal-article" @default.
• W4310127467 hasAuthorship W4310127467A5006107530 @default.
• W4310127467 hasAuthorship W4310127467A5010075752 @default.
• W4310127467 hasAuthorship W4310127467A5012925920 @default.
• W4310127467 hasAuthorship W4310127467A5015788207 @default.
• W4310127467 hasAuthorship W4310127467A5020631581 @default.
• W4310127467 hasAuthorship W4310127467A5022353898 @default.
• W4310127467 hasAuthorship W4310127467A5023810956 @default.
• W4310127467 hasAuthorship W4310127467A5029369362 @default.
• W4310127467 hasAuthorship W4310127467A5041754278 @default.
• W4310127467 hasAuthorship W4310127467A5047764826 @default.
• W4310127467 hasAuthorship W4310127467A5053254720 @default.
• W4310127467 hasAuthorship W4310127467A5056921013 @default.
• W4310127467 hasAuthorship W4310127467A5058195823 @default.
• W4310127467 hasAuthorship W4310127467A5060452476 @default.
• W4310127467 hasAuthorship W4310127467A5062180760 @default.
• W4310127467 hasAuthorship W4310127467A5067600974 @default.
• W4310127467 hasAuthorship W4310127467A5077151480 @default.
• W4310127467 hasAuthorship W4310127467A5087964828 @default.
• W4310127467 hasAuthorship W4310127467A5089354375 @default.
• W4310127467 hasAuthorship W4310127467A5091318797 @default.
• W4310127467 hasBestOaLocation W43101274671 @default.
• W4310127467 hasConcept C104317684 @default.
• W4310127467 hasConcept C109159458 @default.
• W4310127467 hasConcept C127716648 @default.
• W4310127467 hasConcept C142724271 @default.
• W4310127467 hasConcept C2022786 @default.
• W4310127467 hasConcept C203014093 @default.
• W4310127467 hasConcept C2777928532 @default.
• W4310127467 hasConcept C2778461978 @default.
• W4310127467 hasConcept C2780007613 @default.
• W4310127467 hasConcept C2780817109 @default.
• W4310127467 hasConcept C28328180 @default.
• W4310127467 hasConcept C2910840531 @default.
• W4310127467 hasConcept C501734568 @default.
• W4310127467 hasConcept C502942594 @default.
• W4310127467 hasConcept C54355233 @default.
• W4310127467 hasConcept C71924100 @default.
• W4310127467 hasConcept C86803240 @default.
• W4310127467 hasConceptScore W4310127467C104317684 @default.
• W4310127467 hasConceptScore W4310127467C109159458 @default.
• W4310127467 hasConceptScore W4310127467C127716648 @default.
• W4310127467 hasConceptScore W4310127467C142724271 @default.
• W4310127467 hasConceptScore W4310127467C2022786 @default.
• W4310127467 hasConceptScore W4310127467C203014093 @default.
• W4310127467 hasConceptScore W4310127467C2777928532 @default.
• W4310127467 hasConceptScore W4310127467C2778461978 @default.
• W4310127467 hasConceptScore W4310127467C2780007613 @default.
• W4310127467 hasConceptScore W4310127467C2780817109 @default.
• W4310127467 hasConceptScore W4310127467C28328180 @default.
• W4310127467 hasConceptScore W4310127467C2910840531 @default.
• W4310127467 hasConceptScore W4310127467C501734568 @default.
• W4310127467 hasConceptScore W4310127467C502942594 @default.
• W4310127467 hasConceptScore W4310127467C54355233 @default.
• W4310127467 hasConceptScore W4310127467C71924100 @default.
• W4310127467 hasConceptScore W4310127467C86803240 @default.
• W4310127467 hasIssue "Supplement 1" @default.
• W4310127467 hasLocation W43101274671 @default.
• W4310127467 hasOpenAccess W4310127467 @default.
• W4310127467 hasPrimaryLocation W43101274671 @default.
• W4310127467 hasRelatedWork W1600162900 @default.
• W4310127467 hasRelatedWork W1965697056 @default.
• W4310127467 hasRelatedWork W2013158704 @default.
• W4310127467 hasRelatedWork W2031464773 @default.
• W4310127467 hasRelatedWork W2057188689 @default.
• W4310127467 hasRelatedWork W2094445906 @default.
• W4310127467 hasRelatedWork W2100991315 @default.
• W4310127467 hasRelatedWork W2149447718 @default.
• W4310127467 hasRelatedWork W2394797755 @default.

• next